Table 1 Baseline clinical characteristics

Age, mean(year)

62

62

62

65

0.951

0.328

0.336

 rang

36–81

36–81

50–70

47–75

 Male

51(61)

37(60)

8(62)

6(75)

 Female

32(39)

25(40)

5(38)

2(25)

0.901

0.656

0.651

Tumor diameter, mean(mm)

34.8

34.4

34.2

39.3

0.963

0.32

0.261

 range

17.5–80

17.5–80

21–55

25–65

 T2

12(14)

7(11)

4(31)

1(13)

 T3

53(64)

41(66)

5(38)

7(88)

 T4

18(22)

14(23)

4(31)

0(0)

0.08

0.104

0.358

 N0

45(54)

31(50)

8(62)

6(75)

 N1

38(46)

31(50)

5(38)

2(25)

0.449

0.656

0.339

 R0

80(96)

59(95)

13(100)

8(100)

 R1

3(4)

3(5)

0(0)

0(0)

0.755

1

 Ductal adenocarcinoma

76(92)

59(95)

11(85)

6(75)

 Intraductal papillary-mucinous tumor

2(2)

1(2)

0(0)

1(13)

 Mucoepidermoid carcinoma

3(4)

1(2)

1(8)

1(13)

 Neuroendocrine neoplasms

2(2)

1(2)

1(8)

0(0)

0.205

0.809

0.097

 no adjuvant therapy

31(37)

24(39)

3(23)

4(50)

 adjuvant chemotherapy alone

52(63)

38(61)

10(77)

4(50)

0.453

0.346

0.818

 pancreatoduodenectomy

53(64)

53(85)

0(0)

0(0)

 distal pancreatectomy

21(25)

0(0)

13(100)

8(100)

 pancreatoduodenectomy & total pancreatectomy

7(8)

7(11)

0(0)

0(0)

 pancreatoduodenectomy & distal pancreatectomy

2(2)

2(3)

0(0)

0(0)

<0.001

<0.001

 Local only

31(37)

25(40)

4(31)

2(25)

 local & metastasis

52(63)

37(60)

9(69)

6(75)

0.52

1

0.651

Relapse-free time interval, mean(month)

8.4

8.4

6.8

11.1

0.507

0.253

0.38

 range

1.1–43.2

1.1–43.2

1.4–15.5

1.3–39.8